申请人:Bayer Pharma Aktiengesellschaft
公开号:US20160318901A1
公开(公告)日:2016-11-03
The present application relates to novel substituted piperidinyltetrahydroquinolines, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of diabetic microangiopathies, diabetic ulcers on the extremities, in particular for promoting wound healing of diabetic foot ulcers, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardial vascular disorders, thromboembolic disorders and ischaemias, peripheral circulatory disturbances, Raynaud's phenomenon, CREST syndrome, microcirculatory disturbances, intermittent claudication, and peripheral and autonomous neuropathies.
本申请涉及新颖的取代哌啶基四氢喹啉化合物,以及它们的制备方法,其用于治疗和/或预防疾病,并用于制备治疗和/或预防疾病的药物,特别是用于治疗和/或预防糖尿病微血管病变、四肢糖尿病溃疡,特别是促进糖尿病足溃疡愈合、糖尿病心力衰竭、糖尿病冠状微血管心脏疾病、周围和心脏血管疾病、血栓栓塞疾病和缺血症、周围循环障碍、雷诺现象、CREST综合征、微循环障碍、间歇性跛行以及周围和自主神经病变的治疗和/或预防。